Falk Roni T, Brinton Louise A, Dorgan Joanne F, Fuhrman Barbara J, Veenstra Timothy D, Xu Xia, Gierach Gretchen L
Breast Cancer Res. 2013 Apr 22;15(2):R34. doi: 10.1186/bcr3416.
Elevated levels of circulating estrogens are linked to breast cancer risk among postmenopausal women but little is known about the importance of estrogen metabolism. A recently developed liquid chromatography tandem mass spectrometry-based method (LC-MS/MS) measuring a panel of 15 estrogen metabolites (EM) has been evaluated in one study, linking high levels of 2-pathway metabolites relative to the parent estrogens to reduced breast cancer risk. We analyzed this panel of EM in a nested case-control study of postmenopausal breast cancer.
Between 1977 and 1987, 6,915 women provided blood samples to the Columbia Missouri Serum Bank and were followed for incident breast cancer through December 2002. We studied 215 postmenopausal breast cancer cases and 215 matched controls who were postmenopausal and not using exogenous hormones at the time of blood draw. EM were examined individually, grouped by pathway (hydroxylation at the C-2, C-4 or C-16 positions of the steroid ring) and by ratios of the groupings. Logistic regression models controlling for matching and breast cancer risk factors were used to calculate quartile-specific odds ratios (ORs) and 95% CIs.
Significant elevated risks were not observed for individual EM, except for quartiles of 16-epiestriol (P trend = 0.07). The OR for total EM, the parent estrogens estrone and estradiol, and 2-pathway catechol EM (2-hydroxyestrone and 2-hydroxyestradiol) were elevated but the trends were not statistically significant. Among 2-pathway metabolites, risks for the highest levels of 2-hydroxyestrone-3-methyl ether and 2-methoxyestradiol were reduced; ORs for women in the highest versus lowest quartiles were 0.57 (95% CI = 0.33 to 0.99) and 0.53 (95% CI = 0.30 to 0.96), respectively. Overall, women with higher levels of 2-pathway EM had a reduced risk of breast cancer, which remained after accounting for levels of parent EM, 4-pathway EM and 16-pathway EM (all trends, P <0.11).
Women with more extensive hydroxylation along the 2-pathway may have a reduced risk of postmenopausal breast cancer. Further studies are needed to clarify the risks for specific EM and complex patterns of estrogen metabolism. This will require aggregation of EM results from several studies.
绝经后女性循环雌激素水平升高与乳腺癌风险相关,但雌激素代谢的重要性却鲜为人知。一项研究评估了一种最近开发的基于液相色谱串联质谱法(LC-MS/MS)的方法,该方法可测量一组15种雌激素代谢物(EM),发现相对于母体雌激素,高水平的2-途径代谢物与降低的乳腺癌风险相关。我们在一项绝经后乳腺癌的巢式病例对照研究中分析了这组EM。
1977年至1987年间,6915名女性向哥伦比亚密苏里血清库提供了血样,并随访至2002年12月以观察乳腺癌发病情况。我们研究了215例绝经后乳腺癌病例和215名匹配的对照,这些对照均为绝经后女性,且在采血时未使用外源激素。对EM进行了单独检查,并按途径(甾体环C-2、C-4或C-16位的羟基化)和分组比例进行分组。使用控制匹配和乳腺癌风险因素的逻辑回归模型来计算四分位数特异性比值比(OR)和95%置信区间(CI)。
除16-表雌三醇四分位数外(P趋势=0.07),未观察到个体EM有显著升高的风险。总EM、母体雌激素雌酮和雌二醇以及2-途径儿茶酚EM(2-羟基雌酮和2-羟基雌二醇)的OR升高,但趋势无统计学意义。在2-途径代谢物中,2-羟基雌酮-3-甲醚和2-甲氧基雌二醇最高水平的风险降低;最高四分位数与最低四分位数女性的OR分别为0.57(95%CI=0.33至0.99)和0.53(95%CI=0.30至0.96)。总体而言,2-途径EM水平较高的女性患乳腺癌的风险降低,在考虑母体EM、4-途径EM和16-途径EM水平后,这种情况仍然存在(所有趋势,P<0.11)。
沿2-途径有更广泛羟基化的女性绝经后乳腺癌风险可能降低。需要进一步研究以阐明特定EM的风险和雌激素代谢的复杂模式。这将需要汇总多项研究的EM结果。